Search

Your search keyword '"Muñoz-Robles, Jorge Andrés"' showing total 3 results
Start Over Author "Muñoz-Robles, Jorge Andrés" Search Limiters Peer Reviewed
3 results on '"Muñoz-Robles, Jorge Andrés"'

2. Seguridad y efectividad del edoxabán en la práctica clínica tras un año de seguimiento en España. Registro ETNA-AF-EUROPE

Author

Barón-Esquivias, Gonzalo, Roldán Rabadán, Inmaculada, García Quintana, Antonio, Cerezo Manchado, Juan José, Antorrena Miranda, M. Isabel, Gómez-Barrado, José Javier, Pérez Paredes, Matías, Santas, Enrique, Pindado Rodríguez, Javier, Muñoz-Robles, Jorge Andrés, Oliver-Miñarro, Desamparados, and Santamaría Ortiz, María Amparo

Published
2022
Full Text
View/download PDF

3. Use of edoxaban in clinical practice: Comparison of data from the Spanish population in the ETNA-AF-Europe registry.

Author

Barón-Esquivias, Gonzalo, Roldán Rabadán, Inmaculada, García Quintana, Antonio, Cerezo Manchado, Juan José, Antorrena Miranda, Isabel, Gómez-Barrado, José Javier, Pérez Paredes, Matías, Santas, Enrique, Pindado Rodríguez, Javier, Muñoz-Robles, Jorge Andrés, Oliver-Miñarro, Desamparados, Santamaría, Amparo, Rabadán, Inmaculada Roldán, Quintana, Antonio García, Miranda, Isabel Antorrena, Paredes, Matías Pérez, Rodríguez, Javier Pindado, and investigators of ETNA AF Spain

Subjects
PYRIDINE, RESEARCH, STROKE, RESEARCH methodology, ATRIAL fibrillation, ANTICOAGULANTS, ACQUISITION of data, MEDICAL cooperation, EVALUATION research, COMPARATIVE studies, THIAZOLES, LONGITUDINAL method
Abstract

Aim: To ascertain the clinical profile and management of edoxaban in clinical practice. Materials & methods: Prospective, noninterventional postauthorization study of nonselected patients with atrial fibrillation treated with edoxaban from 12 European countries. Patients' baseline characteristics are presented. Results: A total of 13,638 patients (73.6 ± 9.5 years; 76.6/23.4% edoxaban 60/30 mg; CHA2DS2-VASc 3.1; 838 [6.1%] from Spain) were included. In Spain, the percentage of very elderly and fragile patients was greater and the risk of thromboembolism (CHA2DS2-VASc ≥2, 98.0 vs 87.3%; p < 0.001) and bleeding (HAS-BLED, 3.2 vs 2.7; p < 0.001) was greater in patients treated with edoxaban 30 mg. The proportion of patients taking edoxaban 30 mg was similar than in ENGAGE AF-TIMI 48. Conclusion: In Spain, patients treated with edoxaban were older and fragile. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results